BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 20530445)

  • 1. Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy.
    Yamazaki K; Sugio K; Yamanaka T; Hirai F; Osoegawa A; Tagawa T; Fukuyama S; Wataya H; Seto T; Ichinose Y
    Anticancer Res; 2010 Apr; 30(4):1311-5. PubMed ID: 20530445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postrecurrence survival in patients with stage I non-small cell lung cancer.
    Nakagawa T; Okumura N; Ohata K; Igai H; Matsuoka T; Kameyama K
    Eur J Cardiothorac Surg; 2008 Sep; 34(3):499-504. PubMed ID: 18579404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of prognostic factors in patients with stage I non-small cell lung cancer].
    Jiang ZQ; Jiang GL; Shi DR; Zhang RX; Fu XL; Qian H
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):364-8. PubMed ID: 15312349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
    J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Establishment and evaluation of a prognostic prediction model for patients after complete resection of non-small cell lung cancer and multidisciplinary therapy].
    Wei WD; Fu JH; Lin P; Li XD; Yang H; Rong TH; Chen LK
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):672-5. PubMed ID: 19173908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection].
    Wei WD; Wen ZS; Su XD; Lin P; Rong TH; Chen LK
    Ai Zheng; 2007 Nov; 26(11):1231-6. PubMed ID: 17991324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy].
    Zhu XZ; Wang LH; Ou GF; Zhou ZM; Chen DF; Xiao ZF; Feng QF; Zhang HX; Wang M; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):748-53. PubMed ID: 18396686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
    Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
    J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
    Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surgery in non-small cell lung cancer of the superior sulcus: results of a combined preoperative and postoperative irradiation regime].
    Pfannschmidt J; Muley T; Hoffmann H; Dienemann H
    Zentralbl Chir; 2004 Aug; 129(4):270-5. PubMed ID: 15354247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
    Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
    Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival.
    Fujimoto T; Cassivi SD; Yang P; Barnes SA; Nichols FC; Deschamps C; Allen MS; Pairolero PC
    J Thorac Cardiovasc Surg; 2006 Sep; 132(3):499-506. PubMed ID: 16935101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.
    De Pas T; Pelosi G; de Braud F; Veronesi G; Curigliano G; Leon ME; Danesi R; Noberasco C; d'Aiuto M; Catalano G; Viale G; Spaggiari L
    J Clin Oncol; 2004 Dec; 22(24):4966-70. PubMed ID: 15611511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.